Manchester, UK, November 5 2012 – Conformetrix Ltd, a leader in optimising drug discovery and design, will take part in a panel discussion on big pharma partnering at BioCap 20121 in Manchester on November 6 2012. The BioNow conference, bringing together international investors and high quality companies, will highlight the wealth of life sciences expertise across industry and academia in Northern England.
On the panel, CEO Dr Sam Williams will share his insights into optimal partnering strategies as well as thoughts on current trends. Conformetrix is a spin-out from the University of Manchester, working with companies across the sector to optimise drug discovery and design.
Conformetrix’s NMR technology determines accurate three-dimensional structures - or conformations - of drug molecules in their bioactive states. This is achieved without the need for traditional structural information regarding the protein target of each drug and provides researchers with valuable information on how development-stage compounds are likely to interact with their targets. This new information should improve the efficiency and quality of the lead identification, lead optimisation and candidate selection stages of drug discovery programs.
1 BioCap 2012 - the North of England Life Science Investment and Showcase Conference, November 6 2012, Manchester, UK. www.bionow.co.uk/events/biocap2012.aspx
For further information please contact:
Conformetrix Ltd
Sam Williams, CEO +44 (0)7881 588947
Emma Palmer Foster, Strategic Communications Consultant +44 (0)7880 787185
communications@conformetrix.com
About Conformetrix Ltd
Conformetrix is a Manchester, UK-based company focused on optimising drug discovery and design. It was founded in 2008 as a spin-out from the University of Manchester. The company uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. Since Conformetrix’s NMR technology shows what shapes molecules adopt when they are active, it provides high-quality templates for drug discovery and design, and valuable information for drug candidate optimisation. In addition, the data is generated faster and more cheaply than by standard techniques such as X-ray crystallography. Conformetrix has solved structures for several large pharmaceutical companies, as well as developing proprietary drug programmes, and recently signed a collaboration with AstraZeneca. It has been funded since inception by specialist life science investor Aquarius Equity Partners. For more information, please go to http://www.conformetrix.com/.
